Overview

Bezlotoxumab Efficacy and Tolerability in Cancer Patient

Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.
Phase:
Phase 4
Details
Lead Sponsor:
The Cooper Health System